Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;4(3):105-110.
doi: 10.4236/jtr.2016.43013. Epub 2016 Aug 23.

Drug-Induced Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant Tuberculosis: Notes from the Field

Somashekar Munivenkatappa  1 , Singarajipura Anil  2 , Balaji Naik  3 , Tyson Volkmann  4 , Karuna D Sagili  5 , Jayachamarajapura S Akshatha  6 , Shashidhar Buggi  6 , Manchenahalli A Sharada  7 , Sudhendra Kulkarni  8 , Vineet K Chadha  7 , Patrick K Moonan  4
Affiliations

Drug-Induced Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant Tuberculosis: Notes from the Field

Somashekar Munivenkatappa et al. J Tuberc Res. 2016 Sep.

Abstract

We followed 188 euthyroidic persons undergoing treatment for multidrug resistant tuberculosis (MDR-TB) in the state of Karnataka, India to determine the incidence of hypothyroidism during anti-tuberculosis treatment. Overall, among MDR-TB patients with valid thyroid stimulating hormone (TSH) values, about 23% developed hypothyroidism (TSH value ≥10 mIU/ml) during anti-tuberculosis treatment; the majority (74%) occurring after 3 months of treatment. Among 133 patients who received a regimen that contained ethionamide, 42 (32%) developed hypothyroidism. Among 17 patients that received a regimen that contained para-aminosalicylate sodium, 6 (35%) developed hypothyroidism. Among 9 HIV positive patients on anti-retroviral treatment, 4 (44%) developed hypothyroidism. These results differ from previously reported 4% incidence of hypothyroidism amongst patients who passively reported thyroidal symptoms during treatment, suggesting routine serologic monitoring of TSH throughout the course of treatment for MDR-TB is warranted.

Keywords: Hypothyroidism; India; Multidrug Resistance; Thyroid-Stimulating Hormone; Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

No conflicts declared.

References

    1. World Health Organization. Global Tuberculosis Report, 2014 (Drug-Resistant TB, Surveillance and Response) World Health Organization; Geneva, Switzerland: 2015. [WHO/HTM/TB/2015.07]
    1. Central Tuberculosis Division, Directorate General of Health Services. Revised National Tuberculosis Control Programme, Guidelines on programmatic management of drug-resistant tuberculosis (PMDT) in India. 2012 Available at: https://www.medbox.org/guidelines-on-programmatic-management-of-drug-res....
    1. Macgregor AE, Somner AR. The Anti-Thyroid Action of Para-Aminosalicylic Acid. The Lancet. 1954;264:931–936. http://dx.doi.org/10.1016/S0140-6736(54)92552-0. - DOI - PubMed
    1. Drucker D, Eggo MC, Salit IE, Burrow GN. Ethionamide-Induced Goitrous Hypothyroidism. Annals of Internal Medicine. 1984;100:837–839. http://dx.doi.org/10.7326/0003-4819-100-6-837. - DOI - PubMed
    1. Silva GA, Andrade MC, Suguide A, et al. Association between Antiretrovirals and Thyroid Diseases: Across-Sectional Study. Archives of Endocrinology and Metabolism. 2015;59:116–122. http://dx.doi.org/10.1590/2359-3997000000023. - DOI - PubMed

LinkOut - more resources